ArticleFrontiers in oncology2025
Dosimetric advantages of dual-layer MLC in hypofractionated stereotactic radiotherapy for multiple brain metastases: a comparative study with single-layer MLC.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Assessment of LD-V1 radiochromic film low-dose performance for mega-voltage radiotherapy quality assurance.Journal of applied clinical medical physics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to evaluate the dosimetric impact of dual-layer-stacked multi-leaf collimators (MLCs) by comparing stereotactic radiotherapy (SRT) plans for multiple brain metastases (BMs) using the dual-layer MLC of the Halcyon 3.0 system against the single-layer MLC of the Versa HD system. Methods: Eighteen patients with multiple BMs were retrospectively selected for this study. For each patient, five SRT plans were generated: two using the dual-layer MLC (Halcyon 3.0) and three using the single-layer MLC (Versa HD, comprising two coplanar and one non-coplanar plan). All plans were optimized under identical conditions, with dose normalization ensuring 95% of the target volume received 100% of the prescribed dose. Dosimetric parameters such as D Results: The Halcyon 3.0 plans with dual-layer MLC demonstrated superior dosimetric outcomes compared to Versa HD coplanar plans, particularly in reducing V Conclusion: The dual-layer stacked MLC of the Halcyon 3.0 system provides comparable OAR sparing and dose gradients to non-coplanar Versa HD plans in single-isocenter hypofractionated SRT for multiple BMs, with significant improvements over coplanar Versa HD plans. This suggests that Halcyon 3.0 could be a preferred option for such treatments when non-coplanar setups are not feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.